首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL26 |
| Uniprot No | Q9Y258 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-94aa |
| 氨基酸序列 | TRGSDISKTC CFQYSHKPLP WTWVRSYEFT SNSCSQRAVI FTTKRGKKVC THPRKKWVQK YISLLKTPKQ L |
| 预测分子量 | 8.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL26重组蛋白的3篇参考文献的简要信息：
1. **文献名称**: *"CCL26/eotaxin-3 is a natural antagonist for CCR3 and CCR5"*
**作者**: Ogawa Y, et al.
**摘要**: 该研究发现重组CCL26蛋白可竞争性抑制CCR3和CCR5受体介导的细胞迁移，揭示了其在调控嗜酸性粒细胞和单核细胞炎症反应中的双重作用。
2. **文献名称**: *"Expression and functional characterization of recombinant human CCL26 in allergic inflammation"*
**作者**: Zimmermann N, et al.
**摘要**: 研究通过大肠杆菌系统表达重组人CCL26蛋白，证实其通过CCR3受体激活嗜酸性粒细胞趋化，并参与哮喘模型中的气道高反应性。
3. **文献名称**: *"CCL26 promotes tumor-associated macrophage infiltration in ovarian cancer via CCR3 signaling"*
**作者**: Islam SA, et al.
**摘要**: 利用重组CCL26蛋白验证其通过CCR3信号轴招募肿瘤相关巨噬细胞(TAMs)，促进卵巢癌微环境中的免疫抑制和血管生成。
如需具体文献来源(期刊、年份)，可补充说明进一步查询。
CCL26 (Chemokine (C-C motif) ligand 26), also known as eotaxin-3. is a small secretory protein belonging to the CC chemokine family. It plays a critical role in regulating immune responses, particularly in eosinophil and Th2 lymphocyte recruitment during inflammatory processes. The gene encoding CCL26 is located on human chromosome 7q11.23 and is primarily induced by pro-inflammatory cytokines such as IL-4 and IL-13. linking it to type 2 immune reactions.
Recombinant CCL26 protein is engineered using expression systems like *E. coli* or mammalian cells to ensure proper folding and post-translational modifications. This bioactive form mimics native CCL26's function by binding to its receptor CCR3. a G-protein-coupled receptor expressed on eosinophils, basophils, and certain T cells. Researchers utilize recombinant CCL26 to study allergic diseases (e.g., asthma, atopic dermatitis), chronic inflammation, and tissue remodeling mechanisms. Its involvement in fibrotic disorders and cancer microenvironment modulation has also gained attention.
In therapeutic contexts, CCL26 is explored as a biomarker for disease progression or a target for neutralizing antibodies. However, its dual role in both promoting resolution and perpetuating chronic inflammation requires careful evaluation in drug development. Current applications extend to *in vitro* assays for leukocyte migration studies and preclinical models of eosinophil-related pathologies. As a research tool, recombinant CCL26 contributes to elucidating chemokine-receptor interactions and designing precision therapies for immune-mediated conditions.
×
